HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIEHS

This article was originally published in The Rose Sheet

Executive Summary

Christopher Portier, PhD, is appointed to new role as National Institute of Environmental Health Sciences associate director for risk assessment, reflecting the agency's commitment to evaluating human health risks of chemicals, drugs and physical agents, NIEHS announces Jan. 10. In his new position, Portier will "oversee and coordinate risk assessment activities within the NIEHS and apply the results of toxicological studies to national and international" risk assessment efforts, agency says. Portier, who has been at NIEHS since 1981, most recently was National Toxicology Program associate director and served as NIEHS Environmental Toxicology program director. His work at NTP included developing its 21st Century roadmap, which identifies program directions in three areas - refining traditional toxicology assays, developing rapid, mechanism-based predictive screens for environmentally induced diseases and improving the overall utility of NTP products for public health decisions. He will be replaced as NTP associate director in the interim by Allan Dearry, PhD, NIEHS notes...

You may also be interested in...



GermBloc Hand-Sanitizer Class Action Takes Aim At 99.99% Germ-Killing Claim

Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.

Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC

The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.

Virtual Adcom Vet Says In-Person Events May Be Better For Product Approval Recommendations

Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel